Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Acalabrutinib monotherapy in mature B-cell malignancies

Richard Furman • 10 Jun 2020
EHA 2020
Lymphoma Acalabrutinib Ibrutinib
ACE-CL-001

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, discusses the safety of acalabrutinib monotherapy in mature B-cell malignancies and goes on to discuss the long-term follow-up of efficacy data. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Furman

2:46
Combining B-cell receptor antagonists and venetoclax in CLL
Richard Furman • 10 Jun 2020
3:43
BTK inhibtors in CLL
Richard Furman • 10 Jun 2020
17:52
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al. • 12 May 2017

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals